NICE Recommends Nemolizumab (Nemluvio, Galderma) for AD in England and Wales
The National Institute for Health and Care Excellence (NICE) has recommended nemolizumab (Nemluvio, Galderma) for routine funding across England and Wales for moderate-to-severe atopic dermatitis (AD) in its final draft guidance.